Overview of systematic reviews of Shufeng Jiedu Capsules.
10.19540/j.cnki.cjcmm.20210712.501
- Author:
Guo-Qiang XU
1
;
Qi-Liang ZHAO
2
;
Xiao-Yu WANG
1
;
Dong ZHANG
3
;
Shuang FAN
3
;
Hui-Qi ZHANG
2
;
Mu-Tian WANG
1
;
Ming-Hu CHEN
2
;
Min LIU
2
Author Information
1. First Teaching Hospital of Tianjin University of Traditional Chinese Medicine Tianjin 300193, China National Clinical Research Center for Chinese Medicine Acupuncture and Moxibustion Tianjin 300193, China Tianjin University of Traditional Chinese Medicine Tianjin 301617, China.
2. First Teaching Hospital of Tianjin University of Traditional Chinese Medicine Tianjin 300193, China National Clinical Research Center for Chinese Medicine Acupuncture and Moxibustion Tianjin 300193, China.
3. Tianjin Haihe Hospital Tianjin 300350, China.
- Publication Type:Review
- Keywords:
AMSTAR 2;
GRADE;
Shufeng Jiedu Capsules;
overview of systematic reviews
- MeSH:
Capsules;
Drugs, Chinese Herbal/therapeutic use*;
Systematic Reviews as Topic;
Treatment Outcome
- From:
China Journal of Chinese Materia Medica
2022;47(4):1103-1113
- CountryChina
- Language:Chinese
-
Abstract:
At present, there have been many clinical trials and systematic reviews/Meta-analysis proving the good clinical efficacy of Shufeng Jiedu Capsules in the treatment of respiratory diseases, while comprehensive discussion is still required. This article overviews and analyzes the systematic reviews/Meta-analysis of Shufeng Jiedu Capsules to provide evidence support for clinical practice. The systematic reviews/Meta-analysis of Shufeng Jiedu Capsules were searched from CBM, Wanfang, CNKI, VIP, PubMed, EMbase and Cochrane Library. The AMSTAR 2 scale and GRADE system were respectively employed for the evaluation of methodological quality and the grading of evidence quality. Finally, 8 systematic reviews/Meta-analysis published during 2018-2021 were included for analysis. The diseases involved include acute exacerbation of chronic obstructive pulmonary disease, community-acquired pneumonia, acute tonsillitis, acute exacerbation of chronic bronchitis and acute upper respiratory tract infection. The number of included RCTs studies ranged from 8 to 25. The results showed that Shufeng Jiedu Capsules combined with western medicine routine had better therapeutic effect than the latter alone in the treatment of the above five diseases. The reported adverse reactions caused by Shufeng Jiedu Capsules were mainly gastrointestinal discomforts such as mild nausea, diarrhoea and vomiting, with low incidence and mild symptoms, which can be relieved by drug withdrawal. The methodological quality of the included studies was extremely low, and the outcome indicators were mainly of low and very low grades. The efficacy and safety of Shufeng Jiedu Capsules in the clinical treatment of diseases still need to be verified based on more high-quality studies. The relevant clinical research and systematic review/Meta-analysis should pay more attention to methodological quality and reporting standards and strengthen the scientificity of research.
